A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

On Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...

In 2019, the U.S. Food and Drug Administration (FDA) approved the use of a nasal spray ketamine derivative called esketamine (Spravato) to treat depression in adults, according to the National ...

Ketamine therapy is now a mainstream prescription for treatment-resistant depression. Read more at straitstimes.com.